Market Cap (In SEK)
422.17 Million
Revenue (In SEK)
-
Net Income (In SEK)
-215.81 Million
Avg. Volume
95.69 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 4.975-13.8
- PE
- -
- EPS
- -
- Beta Value
- 0.654
- ISIN
- SE0008241491
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jeppe Ovli Ovlesen EE, MBA
- Employee Count
- -
- Website
- https://www.synactpharma.com
- Ipo Date
- 2016-07-11
- Details
- SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
More Stocks
-
RAIL
-
ANNX
-
ALLR
-
TRAD
-
GENGen Digital Inc.
GEN
-
AGNPF
-
WALL-BWallenstam AB (publ)
WALL-B
-
SAI